Rifampin containing regimen — Competitive Intelligence Brief

Rifampin containing regimen (Rifampin containing regimen) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial RNA polymerase inhibitor. Area: Infectious Diseases.

phase 3 Bacterial RNA polymerase inhibitor bacterial RNA polymerase beta subunit Infectious Diseases Small molecule

Target snapshot

Rifampin containing regimen (Rifampin containing regimen) — Nantes University Hospital. Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifampin containing regimen TARGET	Rifampin containing regimen	Nantes University Hospital	phase 3	Bacterial RNA polymerase inhibitor	bacterial RNA polymerase beta subunit
Standard dose rifampicin	Standard dose rifampicin	Radboud University Medical Center	phase 3	Bacterial RNA polymerase inhibitor	beta subunit of bacterial RNA polymerase
PAR-101/OPT-80	PAR-101/OPT-80	Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Non-systemic antibiotic; bacterial RNA polymerase inhibitor	Bacterial RNA polymerase (C. difficile)
Placebo matched to Rifampin	Placebo matched to Rifampin	Hamilton Health Sciences Corporation	phase 3	Bacterial RNA polymerase inhibitor	Bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial RNA polymerase inhibitor class)

1. Hamilton Health Sciences Corporation · 1 drug in this class
2. Nantes University Hospital · 1 drug in this class
3. Radboud University Medical Center · 1 drug in this class